Versión de HTML Básico
254
ST 3.3 –
Protección radiológica en medicina nuclear
DOSE RATE ESTIMATION FOR I¹³¹ ABLATIVE TREATMENTS
Lucena Barros, Juliana Patrícia Pereira
1
*;
Rodrigues Júnior, Cláudio Lucindo
1
; Jesus Filho, Ferdinand Lopes
1
;
Geraldo de Lemos Aragão Filho
2
; Ivan Eufrázio de Santana
3
;
Vandeisson Henrique Coutinho da Silva
1
;
Jeffersson Henrique dos Santos
1
; Islane Cristina Siqueira da Silva
1
1
Instituto Federal de Educação,Ciência e Tecnologia de Pernambuco – IFPE. Brasil.
2
PROCAPE. Brasil.
3
CEMUPE. Brasil.
* Autor responsable, email: julianaabarros@gmail.com
A clinical procedure made after the thyroid gland removal surgery (thyroidectomy) is the
Radioactive Iodine Therapy. That procedure consists in the administration, by orally, of
Radioactive Iodine (I¹³¹ or I¹²³) ablative doses, in order to destroy cancer cells and thyroid tissue
remaining after surgery. The goal of this paper is to evaluate the variation in the exposure rate
in patients who underwent the procedure and are hospitalized into the Medicine Nuclear
service, due to the high activity had been administered, and its possibility to conduct a
dosimetric estimate. A digital Geiger-Muller counter was used as the measuring method, based
on the parameters settled by CNEN, the Brazilian institution regulates applications in Nuclear
Medicine all over the country, by the norm 3.05 (about requirements of safety and Radiation
Protection for Nuclear Medicine services). Some patients undergoing ablatives doses were
selected for this study in a Brazilian Medicine Nuclear service. During the course of data
collection, those patients were evaluated at different distances: direct contact, 0,5, 1 and 2
meters from the patient, and three different measurement times: 10 minutes after the Iodine
administration, 24 hours and 48 hours. As the result, the relationship of the measurements were
satisfactory, it was possible in a practical and comparative nalysis of the provided parameters
by CNEN NN 3:05 and its recent changes. Therefore, we conclude the related numerical
differences to exposure and dose rate for those patients does not exceed over 0.03 mSv/h from
the public, as provided in the regulatory norm.